These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25086186)

  • 1. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
    Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
    Deng N; Goh LK; Wang H; Das K; Tao J; Tan IB; Zhang S; Lee M; Wu J; Lim KH; Lei Z; Goh G; Lim QY; Tan AL; Sin Poh DY; Riahi S; Bell S; Shi MM; Linnartz R; Zhu F; Yeoh KG; Toh HC; Yong WP; Cheong HC; Rha SY; Boussioutas A; Grabsch H; Rozen S; Tan P
    Gut; 2012 May; 61(5):673-84. PubMed ID: 22315472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
    Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
    Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.
    Qian Z; Zhu G; Tang L; Wang M; Zhang L; Fu J; Huang C; Fan S; Sun Y; Lv J; Dong H; Gao B; Su X; Yu D; Zang J; Zhang X; Ji J; Ji Q
    Genes Chromosomes Cancer; 2014 Nov; 53(11):883-94. PubMed ID: 24935174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.
    Ye P; Zhang M; Fan S; Zhang T; Fu H; Su X; Gavine PR; Liu Q; Yin X
    PLoS One; 2015; 10(11):e0143207. PubMed ID: 26587992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
    Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
    Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
    Park YS; Na YS; Ryu MH; Lee CW; Park HJ; Lee JK; Park SR; Ryoo BY; Kang YK
    Am J Clin Pathol; 2015 Jun; 143(6):865-72. PubMed ID: 25972329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
    Saisana M; Griffin SM; May FE
    Oncotarget; 2016 Aug; 7(34):54445-54462. PubMed ID: 27437872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
    Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
    Han N; Kim MA; Lee HS; Kim WH
    Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
    Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
    Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
    Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
    Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.